Advertisement

Medical Oncology

, 32:79 | Cite as

A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma

  • Hongli Zhao
  • Guoxun Sun
  • Desheng Kong
  • Yujing Zhang
  • Wudan Shi
  • Mingming Zhao
  • Luojia Hong
  • Zhenkui QiaoEmail author
Original Paper

Abstract

Limited data have been reported regarding the use of arsenic trioxide (ATO) in the treatment of patients with relapsed or refractory malignant lymphoma; therefore, the present phase II study evaluated the efficacy and toxicity of ATO in such patients. A total of 35 patients were treated with ATO (0.25 mg/kg) infused for 1 h daily, 5 days a week, for a 6-week cycle. Patients were evaluated for the efficacy and toxicity of this regimen. The primary outcome evaluated was the overall response rate (ORR), including the complete and partial response rates. The secondary outcomes evaluated were the overall survival (OS), progression-free survival (PFS), and toxicity. Tumor response data were obtained from all 35 enrolled patients. The ORR was 43 %, including complete responses in four patients (11 %) and partial responses in 11 patients (31 %). The median duration of response was 16 weeks (range 11–23 weeks). The median OS was 79 weeks (range 14–171 weeks), and the median PFS was 55 weeks (range 14–135 weeks). Grade I or II hematological toxicities were the most commonly reported adverse events. The results of this study appear promising for the treatment of relapsed or refractory malignant lymphoma, with well-tolerated ATO toxicity.

Keywords

Arsenic trioxide Lymphoma Non-Hodgkin lymphoma Hodgkin lymphoma 

Notes

Acknowledgments

This study was funded by Heilongjiang Province Science Foundation for Youths (Grant No.QC2012C106).

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    El Helw LM, Lorigan PC, Robinson MH, Coleman RE, Hancock BW. VEDex (vincristine, epirubicin, dexamethasone): an effective and well tolerated palliative chemotherapy regimen for non-Hodgkin’s lymphoma. Int J Oncol. 2000;16:777–82.PubMedGoogle Scholar
  2. 2.
    Shamash J, Lee SM, Radford JA, et al. Patterns of relapse and subsequent management following high dose chemotherapy with autologus haematopoietic supporting relapsed or refractory Hodgkin’s lymphoma: a two centre study. Ann Oncol. 2000;11(6):715–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment ofacute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Huang BT, Zeng QC, Gurung A, Zhao WH, Xiao Z, Li BS. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Med Oncol. 2012;29(3):2088–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–21.CrossRefPubMedGoogle Scholar
  6. 6.
    Yanada M, Tsuzuki M, Fujita H, et al. Japan AdultLeukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013;121(16):3095–102.CrossRefPubMedGoogle Scholar
  7. 7.
    Liu YJ, Wu DP, Liang JY, Qiu HY, Jin ZM, Tang XW, Fu CC, Ma X. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Med Oncol. 2011;28(Suppl 1):S513–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Hussein MA. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma. Med Oncol. 2001;18(4):239–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Abou-Jawde RM, Reed J, Kelly M, et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol. 2006;23(2):263–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM, Farag SS. Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leuk Res. 2008;32(8):1295–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007;13(6):1762–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006;91(12):1722–3.PubMedGoogle Scholar
  13. 13.
    Berenson JR, Boccia R, Siegel D, et al. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol. 2006;135(2):174–83.CrossRefPubMedGoogle Scholar
  14. 14.
    Wei W, Zhou F, Zhang Y, Guo L, Shi H, Hou J. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes. Leuk Res. 2012;36(6):715–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Welch JS, Klco JM, Gao F, et al. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study. Am J Hematol. 2011;86(9):796–800.CrossRefPubMedGoogle Scholar
  16. 16.
    Sekeres MA, Maciejewski JP, Erba HP, et al. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer. 2011;117(6):1253–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Roboz GJ, Ritchie EK, Curcio T, et al. Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leuk Res. 2011;35(4):522–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Raut LS. Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3(1):66–70.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Ahn RW, Barrett SL, Raja MR, et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS ONE. 2013;8(3):e58491.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Wang R, Liu C, Xia L, et al. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p 1–1. Clin Cancer Res. 2012;18(24):6690–701.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Jung HJ, Chen Z, McCarty N. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. Am J Hematol. 2012;87(12):1057–64.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promylecytic leukemia (APL): As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345–53.PubMedGoogle Scholar
  23. 23.
    Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development studies. Oncologist. 2001;6(Suppl 2):22–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Jing Y, Dai J, Chalmers-Redman R, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102–11.PubMedGoogle Scholar
  25. 25.
    Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox systems. Blood. 1999;93:268–77.PubMedGoogle Scholar
  26. 26.
    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMedGoogle Scholar
  27. 27.
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Lazo G, Kantarjian H, Estey E, Thomas D, O’Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer. 2003;97:2218–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011;29(20):2753–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006;24:2456–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006;24:2465–71.CrossRefPubMedGoogle Scholar
  33. 33.
    Lo RK, Kwong YL. Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1. Ann Hematol. 2014;93(2):255–65.CrossRefPubMedGoogle Scholar
  34. 34.
    Nie L, Zhang Y, Zhang JJ, Wang SZ. Combinational effects of bcl-2 antisense oligodeoxynucleotides with arsenic trioxide on malignant lymphoma cell lines. China Oncol. 2002;12(3):197–200.Google Scholar
  35. 35.
    Nie L. Apoptosis induced in malignant lymphoma cells by arsenic trioxide. Ji Nan University, Master’s Thesis. 2000; 1–42.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Hongli Zhao
    • 1
  • Guoxun Sun
    • 1
  • Desheng Kong
    • 1
  • Yujing Zhang
    • 1
  • Wudan Shi
    • 1
  • Mingming Zhao
    • 1
  • Luojia Hong
    • 1
  • Zhenkui Qiao
    • 1
    Email author
  1. 1.Department of HematologyFourth Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations